A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis
Key facts
- Who runs it
- AbbVie
- Where
- Atlanta, Chicago, Cleveland, Jacksonville, Oklahoma City, Roanoke, Silver Spring, and Washington D.C., United StatesSee the 8 sitesAlso in 1 other country, 2 sites
- Trial code
- Status
- Withdrawn
- Phase
- Phase 3
- Started
- 15 Sept 2025
- Ended
- 19 Jul 2026
- Type of study
- Interventional, 2 groups
- Treatments tested
- Mesalamine
- Placebo
- Record updated
- 12 August 2025
- Why it stopped
- strategic considerations
Who can take part
- Age
- 5 years to 17 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Documented history of Ulcerative Colitis (UC) who have been successfully maintained in remission for at least 30 days prior to the screening visit and are on a stable dose of mesalamine or 5-aminosalicylic acid equivalent
Who cannot take part
- Abnormal and clinically significant results according to the investigator or designee, on physical examination, medical history, electrocardiogram (ECG), hematology, clinical chemistry, or urinalysis
Where in United States
Also in 1 other country, 2 sites
- Treken Primary CareAtlanta, United States
- Eagle Clinical ResearchChicago, United States
- UH Cleveland Medical CenterCleveland, United States
- Angel Kids PediatricsJacksonville, United States
- Children's Hospital OklahomaOklahoma City, United States
- Carilion Medical CenterRoanoke, United States
- Virgo Carter PediatricsSilver Spring, United States
- Childrens NationalWashington D.C., United States
About the trial
What the trial wants to find out
Ulcerative colitis (UC) is a type of inflammatory bowel disease (IBD) characterized by diffuse, continuous inflammation of the colon. This study will assess how safe and effective mesalamine delayed-release capsules are in treating pediatric participants with UC. Adverse events and change in disease activity will be assessed.
Read full original descriptionShow less
Delzicol (Mesalamine) is an approved drug being developed for the treatment of Ulcerative Colitis (UC). Study doctors put the participants in 1 of 2 groups, called treatment arms. Each group receives a different treatment. Around 80 Pediatric participants aged 5 to 17 years with a diagnosis of UC will be enrolled in approximately 45 sites in the United States.
Participants will receive oral mesalamine capsules twice daily for 26 weeks and followed for 30 days.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
The 2 groups in the trial
- Mesalamine Dose ATreatment being tested
Participants will receive mesalamine Dose A twice daily for 26 weeks.
Treatment: Mesalamine
- Mesalamine Dose BTreatment being tested
Participants will receive mesalamine Dose B twice daily for 26 weeks.
Treatment: Mesalamine and Placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Double-blind Study to Assess the Safety and Efficacy of Mesalamine Delayed-release Capsules in Children Aged 5 to 17 Years for the Maintenance of Remission of Ulcerative Colitis
- Record updated
- 12 August 2025